Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2022 Earnings Call Transcript

Dave Francisco: Yes, Ryan. I mean the one thing I would say is that, obviously, this is an environment where, from our standpoint, we are looking at flattish top line, absolutely. And you can see there based on the prepared remarks, we also see a decline in gross margin, which is primarily related to the mix shift out of PuraPly. As you might imagine, that’s a fairly profitable business there, franchised. So what we’re trying to do is be prudent about the operating expenses that we’re investing back in. It’s relatively minor. I think the levers we’ve got are we’re digging in pretty deep to ensure that we’re optimizing our €“ all the tools that we have and redeploying resources where they’ll add the most value. So we’re looking at all those different things. And we think that the investment profile that we’ve got going forward, again, to your point, is consistent with where we are around on the top line.

Ryan Zimmerman: Okay. I am going to stop there. And hop back in queue. But appreciate you answered all my questions today.

Gary Gillheeney: Sure, Ryan. Thank you.

Dave Francisco: Thanks, Ryan.

Operator: Thank you. We are currently showing no remaining questions in the queue at this time. That does conclude our conference for today. Thank you for your participation.

Gary Gillheeney: Thank you.